| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rehabilitation Centers | 6 | 2013 | 69 | 1.360 |
Why?
|
| Neoplasms | 19 | 2019 | 15695 | 0.940 |
Why?
|
| Helicobacter pylori | 14 | 2013 | 1321 | 0.940 |
Why?
|
| Inpatients | 3 | 2013 | 701 | 0.670 |
Why?
|
| Meditation | 1 | 2019 | 76 | 0.640 |
Why?
|
| Yoga | 1 | 2019 | 86 | 0.630 |
Why?
|
| Length of Stay | 8 | 2014 | 2025 | 0.620 |
Why?
|
| Subacute Care | 1 | 2017 | 13 | 0.580 |
Why?
|
| Rehabilitation | 1 | 2017 | 37 | 0.570 |
Why?
|
| Spinal Cord Compression | 2 | 2010 | 159 | 0.530 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 69 | 0.520 |
Why?
|
| Heme Oxygenase (Decyclizing) | 3 | 2010 | 20 | 0.510 |
Why?
|
| Heme | 3 | 2012 | 78 | 0.510 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2014 | 398 | 0.500 |
Why?
|
| Activities of Daily Living | 3 | 2011 | 555 | 0.480 |
Why?
|
| Thioctic Acid | 1 | 2013 | 13 | 0.470 |
Why?
|
| Cancer Care Facilities | 6 | 2013 | 905 | 0.460 |
Why?
|
| Sacrum | 2 | 2005 | 135 | 0.430 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 119 | 0.410 |
Why?
|
| Genome, Bacterial | 2 | 2012 | 202 | 0.410 |
Why?
|
| Spinal Neoplasms | 2 | 2010 | 656 | 0.400 |
Why?
|
| Heart Rate | 3 | 2013 | 752 | 0.390 |
Why?
|
| Asthenia | 1 | 2011 | 18 | 0.390 |
Why?
|
| Patient Transfer | 2 | 2012 | 139 | 0.380 |
Why?
|
| Hemipelvectomy | 1 | 2011 | 40 | 0.380 |
Why?
|
| Relaxation Therapy | 1 | 2010 | 19 | 0.370 |
Why?
|
| Recovery of Function | 2 | 2011 | 723 | 0.360 |
Why?
|
| Health Planning | 1 | 2010 | 28 | 0.360 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 572 | 0.360 |
Why?
|
| Resuscitation Orders | 1 | 2010 | 70 | 0.350 |
Why?
|
| Advance Directives | 1 | 2010 | 89 | 0.340 |
Why?
|
| Hospitalization | 4 | 2013 | 2208 | 0.340 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 203 | 0.340 |
Why?
|
| Intensive Care Units | 3 | 2012 | 747 | 0.330 |
Why?
|
| Patient Readmission | 1 | 2013 | 593 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 509 | 0.330 |
Why?
|
| Muscle Spasticity | 2 | 2012 | 83 | 0.320 |
Why?
|
| Azotemia | 1 | 2007 | 2 | 0.300 |
Why?
|
| Hyperglycemia | 1 | 2010 | 338 | 0.300 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2008 | 195 | 0.300 |
Why?
|
| Helicobacter Infections | 7 | 2012 | 1244 | 0.290 |
Why?
|
| Primary Health Care | 1 | 2013 | 847 | 0.290 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 558 | 0.280 |
Why?
|
| Patient Discharge | 3 | 2007 | 709 | 0.280 |
Why?
|
| Hip Joint | 2 | 2004 | 59 | 0.280 |
Why?
|
| Middle Aged | 29 | 2014 | 89413 | 0.270 |
Why?
|
| Lymphoma | 2 | 2013 | 1495 | 0.260 |
Why?
|
| Bacterial Proteins | 5 | 2013 | 1049 | 0.260 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1216 | 0.260 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 638 | 0.250 |
Why?
|
| Aged, 80 and over | 14 | 2014 | 30767 | 0.250 |
Why?
|
| Fecal Incontinence | 1 | 2005 | 87 | 0.250 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 310 | 0.240 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 2506 | 0.240 |
Why?
|
| Urinary Incontinence | 1 | 2005 | 147 | 0.240 |
Why?
|
| Neuromuscular Agents | 2 | 2012 | 86 | 0.240 |
Why?
|
| Aged | 22 | 2014 | 72800 | 0.240 |
Why?
|
| Nutritional Support | 1 | 2004 | 79 | 0.240 |
Why?
|
| Adult | 23 | 2013 | 80581 | 0.230 |
Why?
|
| Hip Contracture | 1 | 2003 | 2 | 0.230 |
Why?
|
| Prone Position | 1 | 2003 | 60 | 0.220 |
Why?
|
| Male | 30 | 2014 | 127406 | 0.220 |
Why?
|
| Transportation of Patients | 1 | 2003 | 59 | 0.220 |
Why?
|
| Radial Nerve | 1 | 2002 | 4 | 0.210 |
Why?
|
| Trauma, Nervous System | 1 | 2002 | 11 | 0.210 |
Why?
|
| Clothing | 1 | 2002 | 23 | 0.200 |
Why?
|
| Botulinum Toxins | 1 | 2004 | 136 | 0.200 |
Why?
|
| Immobilization | 1 | 2002 | 95 | 0.200 |
Why?
|
| Female | 33 | 2014 | 147053 | 0.200 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 235 | 0.200 |
Why?
|
| Hemin | 3 | 2010 | 24 | 0.200 |
Why?
|
| Ossification, Heterotopic | 1 | 2002 | 71 | 0.200 |
Why?
|
| Malnutrition | 1 | 2004 | 224 | 0.200 |
Why?
|
| Humans | 40 | 2019 | 270404 | 0.200 |
Why?
|
| Molecular Sequence Data | 7 | 2013 | 6123 | 0.180 |
Why?
|
| Wounds, Gunshot | 1 | 2002 | 108 | 0.180 |
Why?
|
| Postoperative Complications | 3 | 2011 | 5817 | 0.180 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2002 | 179 | 0.180 |
Why?
|
| Wound Healing | 1 | 2005 | 829 | 0.180 |
Why?
|
| Chordoma | 1 | 2002 | 168 | 0.180 |
Why?
|
| Interleukin-17 | 3 | 2010 | 264 | 0.170 |
Why?
|
| Quality of Life | 1 | 2013 | 4719 | 0.170 |
Why?
|
| Pain Measurement | 4 | 2014 | 995 | 0.160 |
Why?
|
| Iron | 3 | 2012 | 378 | 0.160 |
Why?
|
| Retrospective Studies | 14 | 2014 | 39440 | 0.160 |
Why?
|
| Creatinine | 3 | 2012 | 550 | 0.150 |
Why?
|
| Social Work | 1 | 2007 | 26 | 0.150 |
Why?
|
| Gastric Mucosa | 2 | 2012 | 622 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1240 | 0.140 |
Why?
|
| Young Adult | 8 | 2013 | 22096 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 1595 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2004 | 713 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1354 | 0.140 |
Why?
|
| Comorbidity | 2 | 2017 | 2454 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 10254 | 0.130 |
Why?
|
| Incidence | 3 | 2013 | 5887 | 0.120 |
Why?
|
| Paraneoplastic Cerebellar Degeneration | 1 | 2014 | 4 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 16258 | 0.120 |
Why?
|
| Electroacupuncture | 1 | 2014 | 35 | 0.120 |
Why?
|
| Staphylococcal Vaccines | 1 | 2013 | 3 | 0.120 |
Why?
|
| Amino Acid Sequence | 5 | 2013 | 4278 | 0.120 |
Why?
|
| Social Support | 1 | 2007 | 581 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 7 | 2013 | 2401 | 0.110 |
Why?
|
| Heart Function Tests | 1 | 2013 | 73 | 0.110 |
Why?
|
| Vaccines, Subunit | 1 | 2013 | 126 | 0.110 |
Why?
|
| Phenol | 1 | 2012 | 18 | 0.110 |
Why?
|
| Tibet | 1 | 2012 | 11 | 0.110 |
Why?
|
| Arginase | 1 | 2013 | 44 | 0.110 |
Why?
|
| Placebos | 1 | 2013 | 448 | 0.110 |
Why?
|
| Stress, Psychological | 2 | 2010 | 1033 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 790 | 0.100 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2012 | 90 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2013 | 119 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2013 | 1581 | 0.100 |
Why?
|
| Multiple Myeloma | 3 | 2014 | 2235 | 0.100 |
Why?
|
| Minisatellite Repeats | 1 | 2011 | 52 | 0.100 |
Why?
|
| Bacterial Adhesion | 1 | 2012 | 145 | 0.100 |
Why?
|
| Immunity | 1 | 2013 | 359 | 0.100 |
Why?
|
| Treatment Outcome | 8 | 2014 | 34163 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 706 | 0.090 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2010 | 41 | 0.090 |
Why?
|
| Bordetella pertussis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Pertussis Toxin | 1 | 2010 | 59 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2011 | 49 | 0.090 |
Why?
|
| Pertussis Vaccine | 1 | 2010 | 28 | 0.090 |
Why?
|
| Nerve Block | 1 | 2012 | 180 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 306 | 0.090 |
Why?
|
| Plasmids | 1 | 2012 | 843 | 0.090 |
Why?
|
| Adhesins, Bacterial | 1 | 2010 | 84 | 0.090 |
Why?
|
| Schools, Medical | 1 | 2011 | 136 | 0.090 |
Why?
|
| Survival | 1 | 2010 | 176 | 0.090 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2012 | 193 | 0.090 |
Why?
|
| Uterine Neoplasms | 1 | 2014 | 566 | 0.090 |
Why?
|
| Crystallography, X-Ray | 4 | 2013 | 644 | 0.090 |
Why?
|
| Pain Management | 2 | 2013 | 703 | 0.090 |
Why?
|
| Stomach Diseases | 1 | 2009 | 64 | 0.080 |
Why?
|
| Texas | 3 | 2007 | 6454 | 0.080 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 214 | 0.080 |
Why?
|
| RNA, Bacterial | 1 | 2009 | 81 | 0.080 |
Why?
|
| Palliative Care | 2 | 2011 | 2130 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2652 | 0.080 |
Why?
|
| Urease | 1 | 2008 | 62 | 0.080 |
Why?
|
| Th1 Cells | 1 | 2010 | 259 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2010 | 240 | 0.080 |
Why?
|
| Th17 Cells | 1 | 2010 | 172 | 0.080 |
Why?
|
| Bacterial Vaccines | 1 | 2008 | 103 | 0.080 |
Why?
|
| Adolescent | 6 | 2011 | 32250 | 0.080 |
Why?
|
| Stomach Neoplasms | 2 | 2012 | 2335 | 0.080 |
Why?
|
| Physical Therapy Modalities | 2 | 2014 | 97 | 0.080 |
Why?
|
| Acupuncture Therapy | 1 | 2009 | 93 | 0.080 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 86 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 674 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2013 | 2661 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2008 | 249 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 5531 | 0.070 |
Why?
|
| Appetite Stimulants | 1 | 2007 | 14 | 0.070 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 97 | 0.070 |
Why?
|
| Prealbumin | 1 | 2007 | 37 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2010 | 328 | 0.070 |
Why?
|
| Cathartics | 1 | 2007 | 43 | 0.070 |
Why?
|
| Appetite | 1 | 2007 | 70 | 0.070 |
Why?
|
| Risk Factors | 3 | 2010 | 18229 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 1607 | 0.070 |
Why?
|
| Dehydration | 1 | 2007 | 89 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2013 | 1222 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 244 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 592 | 0.070 |
Why?
|
| Sequence Alignment | 1 | 2008 | 847 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2012 | 2111 | 0.070 |
Why?
|
| Stomach | 1 | 2009 | 391 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2009 | 726 | 0.070 |
Why?
|
| Education, Medical | 1 | 2011 | 359 | 0.070 |
Why?
|
| Cisplatin | 1 | 2013 | 2456 | 0.070 |
Why?
|
| Constipation | 1 | 2007 | 180 | 0.070 |
Why?
|
| Epitopes | 1 | 2008 | 696 | 0.070 |
Why?
|
| China | 3 | 2013 | 626 | 0.070 |
Why?
|
| United States | 3 | 2013 | 16302 | 0.070 |
Why?
|
| Catheterization | 1 | 2008 | 430 | 0.070 |
Why?
|
| Lumbosacral Plexus | 1 | 2005 | 12 | 0.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2007 | 135 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2007 | 222 | 0.060 |
Why?
|
| Spinal Nerve Roots | 1 | 2005 | 66 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2011 | 9476 | 0.060 |
Why?
|
| Colostomy | 1 | 2005 | 79 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2007 | 480 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2007 | 321 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 997 | 0.060 |
Why?
|
| G2 Phase | 1 | 2005 | 213 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 15182 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1280 | 0.060 |
Why?
|
| Movement | 2 | 2010 | 564 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2007 | 341 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2009 | 1455 | 0.060 |
Why?
|
| Analgesics | 1 | 2007 | 400 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 807 | 0.060 |
Why?
|
| Nutritional Requirements | 1 | 2004 | 187 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2008 | 1472 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2010 | 2857 | 0.060 |
Why?
|
| Hip | 1 | 2003 | 30 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 1372 | 0.060 |
Why?
|
| Communication | 1 | 2010 | 908 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 257 | 0.060 |
Why?
|
| Postoperative Period | 1 | 2005 | 672 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2941 | 0.050 |
Why?
|
| Walking | 1 | 2005 | 274 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 889 | 0.050 |
Why?
|
| Vecuronium Bromide | 1 | 2002 | 2 | 0.050 |
Why?
|
| Carcinoma | 1 | 2014 | 2600 | 0.050 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2004 | 4460 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 1347 | 0.050 |
Why?
|
| Pain | 2 | 2009 | 1693 | 0.050 |
Why?
|
| Computational Biology | 1 | 2009 | 1298 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5028 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1405 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1630 | 0.050 |
Why?
|
| Range of Motion, Articular | 1 | 2002 | 145 | 0.050 |
Why?
|
| Bacterial Typing Techniques | 2 | 2012 | 141 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2002 | 348 | 0.050 |
Why?
|
| Fatigue | 1 | 2007 | 1267 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 4383 | 0.050 |
Why?
|
| Age Factors | 1 | 2010 | 5490 | 0.050 |
Why?
|
| Survival Rate | 2 | 2004 | 12428 | 0.050 |
Why?
|
| Conserved Sequence | 2 | 2012 | 468 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2013 | 1226 | 0.040 |
Why?
|
| Boronic Acids | 2 | 2014 | 364 | 0.040 |
Why?
|
| Bortezomib | 2 | 2014 | 549 | 0.040 |
Why?
|
| Anxiety | 1 | 2007 | 1240 | 0.040 |
Why?
|
| Child | 4 | 2011 | 30092 | 0.040 |
Why?
|
| Cytarabine | 1 | 2005 | 1993 | 0.040 |
Why?
|
| Pyrazines | 2 | 2014 | 508 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2005 | 959 | 0.040 |
Why?
|
| Thalidomide | 2 | 2014 | 577 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4730 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 620 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 1942 | 0.040 |
Why?
|
| Hypertension | 1 | 2007 | 1582 | 0.040 |
Why?
|
| Mice | 7 | 2013 | 35283 | 0.040 |
Why?
|
| Animals | 9 | 2013 | 60938 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 1503 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2013 | 1766 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2010 | 1162 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 1506 | 0.030 |
Why?
|
| Speech Therapy | 1 | 2014 | 13 | 0.030 |
Why?
|
| Counseling | 1 | 2007 | 386 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 4845 | 0.030 |
Why?
|
| Opsonin Proteins | 1 | 2013 | 16 | 0.030 |
Why?
|
| Occupational Therapy | 1 | 2014 | 47 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2005 | 1919 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 3595 | 0.030 |
Why?
|
| Genotype | 2 | 2012 | 4166 | 0.030 |
Why?
|
| Hospitals, County | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 2013 | 27 | 0.030 |
Why?
|
| Hemiterpenes | 1 | 2012 | 6 | 0.030 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2012 | 4 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 5238 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 94 | 0.030 |
Why?
|
| Hospital Units | 1 | 2012 | 38 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 4995 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2013 | 390 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2012 | 132 | 0.030 |
Why?
|
| Magnesium | 1 | 2013 | 163 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 86 | 0.030 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2012 | 9 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2012 | 71 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2013 | 274 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 150 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 2012 | 104 | 0.030 |
Why?
|
| Chemokines | 1 | 2013 | 318 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2012 | 58 | 0.030 |
Why?
|
| Injections | 1 | 2012 | 288 | 0.030 |
Why?
|
| Immunization | 1 | 2013 | 402 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 338 | 0.030 |
Why?
|
| Stomach Ulcer | 1 | 2012 | 94 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2004 | 7162 | 0.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2012 | 126 | 0.020 |
Why?
|
| Molecular Docking Simulation | 1 | 2012 | 169 | 0.020 |
Why?
|
| Duodenal Ulcer | 1 | 2012 | 116 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 11816 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2013 | 369 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 494 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2010 | 5663 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 307 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 278 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 692 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 620 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2007 | 933 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 281 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 231 | 0.020 |
Why?
|
| Protein Refolding | 1 | 2010 | 2 | 0.020 |
Why?
|
| Azides | 1 | 2010 | 32 | 0.020 |
Why?
|
| Th1-Th2 Balance | 1 | 2010 | 12 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 649 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2010 | 32 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2010 | 42 | 0.020 |
Why?
|
| Leukocytosis | 1 | 2010 | 114 | 0.020 |
Why?
|
| Dimerization | 1 | 2010 | 311 | 0.020 |
Why?
|
| Parasympathetic Nervous System | 1 | 2010 | 27 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 13251 | 0.020 |
Why?
|
| Death | 1 | 2011 | 119 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 16050 | 0.020 |
Why?
|
| Lac Operon | 1 | 2009 | 123 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 1059 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2009 | 220 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 5913 | 0.020 |
Why?
|
| Mifepristone | 1 | 2009 | 153 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 569 | 0.020 |
Why?
|
| Crystallization | 1 | 2009 | 136 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 978 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2010 | 482 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2010 | 163 | 0.020 |
Why?
|
| Phylogeny | 1 | 2011 | 844 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 162 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2009 | 144 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2009 | 14501 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 302 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 7414 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2010 | 265 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2008 | 171 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2208 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2009 | 198 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 386 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2008 | 91 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 2362 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 1232 | 0.020 |
Why?
|
| Gastritis | 1 | 2012 | 379 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2008 | 308 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 571 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 284 | 0.020 |
Why?
|
| Transgenes | 1 | 2009 | 569 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 509 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 325 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2012 | 854 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2010 | 12135 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2010 | 751 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3479 | 0.020 |
Why?
|
| Students, Medical | 1 | 2011 | 430 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2008 | 1271 | 0.020 |
Why?
|
| Prognosis | 1 | 2003 | 22228 | 0.020 |
Why?
|
| Staurosporine | 1 | 2005 | 144 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1260 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3519 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 902 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 1409 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 1057 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 1848 | 0.020 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 180 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2005 | 180 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 2113 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 5126 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1347 | 0.010 |
Why?
|
| Leukemia | 1 | 2012 | 1653 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 573 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 2480 | 0.010 |
Why?
|
| Cognition | 1 | 2010 | 1000 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3664 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 1584 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 623 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 4929 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2005 | 888 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 3955 | 0.010 |
Why?
|
| Kidney | 1 | 2009 | 2183 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 5794 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6265 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 3089 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 6222 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2011 | 1472 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2010 | 4165 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 7154 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2010 | 9320 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 1978 | 0.010 |
Why?
|
| DNA Damage | 1 | 2005 | 1987 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 4442 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 7757 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 14849 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2005 | 7061 | 0.000 |
Why?
|